News

Filter

Current filters:

None

82 to 91 of 96511 results

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

Positive Ph III results for Ipsen’s Decapeptyl in prostate cancer patients

12-10-2014

French drugmaker Ipsen has released positive results from the Phase III study of Decapeptyl (triptorelin…

DecapeptylIpsenOncologyPharmaceuticalResearch

Highlights from EMA Pharmacovigilance October meeting

10-10-2014

At its October meeting, the European Medicines Agency’ Pharmacovigilance Risk Assessment Committee…

Ariad PharmaceuticalsEuropeIclusigMen's HealthNeurologicalOncologyPharmaceuticalRegulationTestosteronevalproate

BTG settles CroFab patent litigation with Bioclon and RDT

10-10-2014

UK specialist health care company BTG says it has settled its US patent infringement complaint against…

BTGCrofabInstituto BioclonLegalPatentsPharmaceuticalRare Disease TherapeuticsRare diseasesUSA

New Zealand approval of Novartis multiproduct proposal

10-10-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

NeurologicalNew ZealandOncologyPharmaceuticalRegulationRespiratory and Pulmonary

IQWiG finds added benefit of Novartis’ Gilenya not proven

IQWiG finds added benefit of Novartis’ Gilenya not proven

10-10-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

GermanyGilenyaNeurologicalNovartisPharmaceuticalPricingRegulation

82 to 91 of 96511 results

Parexel

Parexel

Back to top